Drawing for TAGABODY

USPTO serial 77480302

TAGABODY

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SWIFT, GILBERT M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TAGABODY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John W. Wallen, III

10975 N TORREY PINES RDLA JOLLA, CA 92037-1051UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Enzymes for scientific and research purposes; biological reagents for research purposes for use in the development of monoclonal and polyclonal antibodies; biological reagents for research purposes used in laboratory, clinical and medical applicationsACTIVE—
005Pharmaceutical preparations comprised of polypeptides for the treatment and/or prevention of human, animal and livestock diseases, namely, cardiovascular disease, metabolic disease, autoimmune disease, diabetes, obesity, inflammatory disease, vascular disease, dermatological disease, ocular disease, hematological disease, neurological disease, gastrointestinal disease, respiratory disease, infectious disease, cancer, allergies, allograft rejection, genetic disorders, diseases of the musculoskeletal and nervous system, and wound healing; pharmaceutical preparations comprised of polypeptides for imaging, namely, radiochemistry and bioconjugation agents for in vivo imaging; pharmaceutical preparations, namely, analgesics; vaccines; biological medical reagents for use in clinical and medical tests for the diagnosis and measurement of disease progression in human, animal and livestock diseases; biological medical reagents for use in clinical and medical imaging; vaccine adjuvants, namely, proteins for use in presenting antigensACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jan 31, 2011MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 31, 2011ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 30, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Jun 28, 2010EX2GSOU EXTENSION 2 GRANTED—
Jun 28, 2010EXT2SOU EXTENSION 2 FILED—
Jun 28, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 20, 2009EX1GSOU EXTENSION 1 GRANTED—
Dec 20, 2009EXT1SOU EXTENSION 1 FILED—
Dec 20, 2009EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 30, 2009NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 7, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 18, 2009NPUBNOTICE OF PUBLICATION—
Mar 2, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 26, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 26, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 26, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 26, 2009ALIEASSIGNED TO LIE—
Feb 25, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 10, 2008CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 9, 2008CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 5, 2008DOCKASSIGNED TO EXAMINER—
May 28, 2008MPMKNOTICE OF PSEUDO MARK MAILED—
May 27, 2008NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance